An observational study in Brow Ptosis, Skin Aging and Facial Aging, sponsored by Estelab Clinic. Completed at 1 site in Russia. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Estelab Clinic · Observational
This observational study describes the results of a routine aesthetic treatment for mild to moderate eyebrow drooping (brow ptosis). Thirty-six adults who came to Klinika Estelab (Moscow) asking for rejuvenation of the upper face received, as part of their usual care, one combined treatment session: microfocused ultrasound with visualization (Ultherapy), abobotulinumtoxinA (Dysport) injections, and hyaluronic acid filler in the temples, with a routine toxin touch-up after 2 weeks. The investigators did not assign any treatment; they only added standardized assessments. Eyebrow height was measured on standardized photographs before treatment, immediately after treatment, and at 1, 3, 6, and 12 months. Aesthetic improvement, patient satisfaction, procedural pain, and side effects were also recorded.
Adults aged 35-65 years with mild to moderate brow ptosis (grade 2-3 on the Merz brow positioning grading scale) who independently sought aesthetic rejuvenation of the upper face at Klinika Estelab (Moscow, Russia) received the clinic's standard combined treatment in one session: microfocused ultrasound with visualization (MFU-V; DS 10-1.5 transducer, 10 MHz, 1.5 mm focal depth), abobotulinumtoxinA injections to the forehead, glabella, and lateral canthal area, and supraperiosteal temporal hyaluronic acid filler after vascular mapping, followed by a routine abobotulinumtoxinA touch-up at 2 weeks. Treatments were part of routine clinical care and were not assigned by the investigators. Outcomes were assessed with standardized photography (FotoFinder) and photogrammetric measurement of mean and maximum eyebrow height by two blinded dermatologists, temporal ultrasound, the Global Aesthetic Improvement Scale (independent blinded physician and patient), the FACE-Q Satisfaction with Upper Eyelids scale (baseline and 12 months), procedural pain (0-10 numeric rating scale), and adverse events at each visit. The study was approved by the Local Ethics Committee of Klinika Estelab LLC (protocol No. 3, 14 December 2023), and all participants gave written informed consent. The study was registered retrospectively.
Estelab Clinic is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults aged 35-65 years with mild to moderate brow ptosis who independently sought aesthetic rejuvenation of the upper face at Klinika Estelab (Moscow, Russia).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with mild to moderate brow ptosis who independently sought aesthetic rejuvenation of the upper face and received the clinic's standard single-session combined treatment as part of routine clinical care. Treatments were not assigned by the investigators.
Device: Microfocused ultrasound with visualization · Drug: AbobotulinumtoxinA · Device: Hyaluronic acid filler
Single session of microfocused ultrasound with visualization (Ultherapy, Merz Aesthetics) using the DS 10-1.5 transducer (10 MHz, 1.5 mm focal depth), performed as part of routine clinical care.
Also known as: Ultherapy, Ulthera System
Intramuscular injections to the forehead, glabella, and lateral canthal area (total 100-200 Speywood units) in the same session, followed by a routine touch-up at 2 weeks, as part of routine clinical care.
Also known as: Dysport
Supraperiosteal injection into the temporal region with a needle after ultrasound vascular mapping, in the same session, as part of routine clinical care.
Also known as: ART FILLER Universal
Change From Baseline in Mean Eyebrow Height
Mean of six standardized distances (mm) from the line through the medial canthi to the upper edge of the eyebrow, measured on standardized photographs by two blinded dermatologists; right and left values averaged.
Time frame: Baseline, immediately after treatment, and 1, 3, 6, and 12 months after treatment
Change From Baseline in Maximum Eyebrow Height
Largest of six standardized distances (mm) from the line through the medial canthi to the upper edge of the eyebrow, measured on standardized photographs by two blinded dermatologists; right and left values averaged.
Time frame: Baseline, immediately after treatment, and 1, 3, 6, and 12 months after treatment
Number of Participants With Adverse Events
Adverse events identified by clinical examination at each visit, including type, severity, and duration.
Time frame: From treatment to 12 months
Global Aesthetic Improvement Scale (GAIS) Score
Five-point scale (1 = very much improved, 2 = much improved, 3 = improved, 4 = no change, 5 = worse), rated separately by an independent blinded physician and by the participant.
Time frame: Immediately after treatment and 1, 3, 6, and 12 months after treatment
FACE-Q Satisfaction With Upper Eyelids Score
Patient-reported FACE-Q Eye Module scale, Rasch-transformed score from 0 (worst) to 100 (best).
Time frame: Baseline and 12 months after treatment
Procedural Pain
Pain during microfocused ultrasound rated on a 0-10 numeric rating scale (0 = no pain, 10 = worst imaginable pain).
Time frame: During the procedure (day 0)
Change in Eyebrow Height According to Facial Aging Type
Exploratory comparison of changes in mean and maximum eyebrow height (mm) between facial aging types.
Time frame: Baseline to 12 months after treatment
Plan to share: No — Individual participant data will not be publicly shared. Data supporting the findings of this study are available from the corresponding author upon reasonable request.
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in May 2026, 28 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Estelab Clinic